2026 Competition Sales 
PM360
SEPTEMBER 21, 2023
They do not have biosimilar or generic competition available in the market. Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. They do not qualify for any exemption (e.g.,
PM360
SEPTEMBER 21, 2023
Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Spotio
APRIL 21, 2023
Recent research shows that the hardware as a service market (HaaS) should reach $300+ billion in 2026. If your reps don’t actually use said research to contact and convert leads, your company won’t make sales. You can then adjust your department’s sales strategy to suit. More sales in less time.
pharmaphorum
JANUARY 10, 2023
billion by 2026, according to research by the Business Research Company. If you have to wait to extract meaning from your data then you won’t be competitive enough. “A This dynamic approach can also be used to predict and recommend next-best actions in sales and marketing, while both improving the customer experience and ROI.
PM360
APRIL 7, 2023
However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. Given the volume of 340B sales (13% of total U.S. Quality and value measurements commonly used outside of the U.S. The 340B battle will rage on.
Evolve Your Success
JANUARY 24, 2023
In this episode, Samuel Adeyinka interviews Caitlin Baker , who shares her journey of transitioning from nursing to aesthetics device sales representative. It’s because she’s a graduate of our Medical Sales Career Builder program. Caitlin was a nurse that wanted to get into medical sales. Her story is unique.
pharmaphorum
OCTOBER 17, 2022
It remains to be seen whether the data from VALOR will convince the regulator to grant conditional approval while it waits for results from a confirmatory phase 3 trial (ATLAS ) in SOD1-ALS, which is due to generate results in 2026.
Expert insights. Personalized for you.
111 
Let's personalize your content